Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HIV PROTEASE GENOTYPE AND VIRAL SENSITIVITY TO HIV PROTEASE INHIBITORS FOLLOWING SAQUINAVIR THERAPY
Autore:
CRAIG C; RACE E; SHELDON J; WHITTAKER L; GILBERT S; MOFFATT A; ROSE J; DISSANAYEKE S; CHIRN GW; DUNCAN IB; CAMMACK N;
Indirizzi:
ROCHE DISCOVERY WELWYN,40 BROADWATER RD WELWYN GARDEN CIT AL7 3AY HERTS ENGLAND HOFFMANN LA ROCHE INC NUTLEY NJ 07110
Titolo Testata:
AIDS
fascicolo: 13, volume: 12, anno: 1998,
pagine: 1611 - 1618
SICI:
0269-9370(1998)12:13<1611:HPGAVS>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VIVO; RESISTANCE; PROTEINASE; VARIANTS; INFECTIVITY; SELECTION; MUTANTS; DESIGN;
Keywords:
HIV PROTEASE; HIV PROTEINASE; SAQUINAVIR; RESISTANCE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
C. Craig et al., "HIV PROTEASE GENOTYPE AND VIRAL SENSITIVITY TO HIV PROTEASE INHIBITORS FOLLOWING SAQUINAVIR THERAPY", AIDS, 12(13), 1998, pp. 1611-1618

Abstract

Objective: To examine the relationship between HIV protease genotype and altered protease inhibitor sensitivity of isolates from patients after therapy with saquinavir (SQV) in its hard gelatin formulation. Design: Forty-one post-therapy isolates and corresponding baseline samples were obtained from 37 patients in four different clinical trials after therapy with SQV for 16-147 weeks. Post-therapy isolates were selected on the basis of preliminary sequence or drug sensitivity data. Results: Fifteen out of 17 isolates without detectable Val-48 or Met-90 mutations retained sensitivity to SQV. (The remaining isolates showed only a marginal increase in median inhibitory concentration. ) In addition, three out of 15 isolates with Met-90 retained sensitivity to ail other protease inhibitors tested (indinavir, ritonavir, amprenavir, nelfinavir). Of the isolates showing reduced sensitivity to SQV, six outof 22 retained sensitivity to all other protease inhibitors, whereas only four out of 22 showed broad cross-resistance to all protease inhibitors tested. The reduction in sensitivity correlated closely with the presence of Val-48 or Met-90. Subsequent accessory substitutions were also linked to reduced sensitivity. However, significant linkage wasobserved only between mutations at residues 48 and 82 and between those at residues 82 and 74. Conclusions: Recruitment of Val-48/Met-90 mutations was not found to be synonymous with cross-resistance. Indeed, the majority of isolates with these mutations retained sensitivity to at least one protease inhibitor (Val-48, 86%; Met-90, 77%). The recruitment of accessory mutations may occur only after the selection of keyresistance mutations. Furthermore, Met-90 was found to be a poor marker of cross-resistance in SQV-treated patients. (C) 1998 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 06:26:08